RBC Capital raises Danaher stock price target on peer valuation

RBC Capital upgraded Danaher Corp.'s stock price target to $250 from $215, maintaining an Outperform rating, according to a report on Sunday. The company's shares are currently trading at $214.87, with a market capitalization of $150.8 billion. The price raise is attributed to an expansion in Danaher's peer group valuation, rather than company-specific factors, according to RBC Capital.

The firm expects more positive company-specific developments heading into the third quarter. Danaher operates in the Life Sciences Tools & Services sector and is set to release earnings on October 21. The updated price target was issued by analyst Dan Leonard on Sunday. Danaher has also recently appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026, and reaffirmed its financial guidance for the third quarter and full year 2026.

Other analysts have provided mixed assessments of Danaher, with UBS setting a buy rating and price target of $250, and TD Cowen lowering its price target to $236 while maintaining a Buy rating due to delays in Danaher's bioproduction segment. In the biopharma sector, funding rose by 42% in September 2026 compared to the previous month and 56% year-over-year, reaching $13.0 billion.

Morgan Stanley analysts highlighted Waters Corporation's strong position in the market following China's new clinical laboratory service pricing framework, which includes tiered discounts and detailed treatment for advanced workflows.